(NASDAQ: KALA) Kala Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 369.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.04%.
Kala Bio's earnings in 2025 is -$35,651,000.On average, 4 Wall Street analysts forecast KALA's earnings for 2025 to be -$35,842,426, with the lowest KALA earnings forecast at -$40,722,374, and the highest KALA earnings forecast at -$30,162,380. On average, 4 Wall Street analysts forecast KALA's earnings for 2026 to be -$5,818,127, with the lowest KALA earnings forecast at -$7,840,954, and the highest KALA earnings forecast at -$3,577,209.
In 2027, KALA is forecast to generate -$2,632,578 in earnings, with the lowest earnings forecast at -$2,529,340 and the highest earnings forecast at -$2,710,007.